Multivariable analysis for PFS and OS in patients with CCUS
| Model . | Variable . | HR (95% CI) . | P value . | C index . |
|---|---|---|---|---|
| PFS | ||||
| Clinical | Exposure to therapy | 1.98 (1.10-3.56) | .023 | |
| Lower Hb | 1.11 (0.93-1.33) | .250 | ||
| Lower PLT | 1.01 (1.01-1.01) | .014 | ||
| Higher RDW | 1.19 (1.07-1.31) | <.001 | 0.751 | |
| Higher MCV | 1.01 (0.98-1.05) | .463 | ||
| Modified CHRS | Exposure to therapy | 2.34 (1.35-4.05) | .002 | |
| Higher CHRS Score | 1.38 (1.19-1.60) | <.001 | 0.688 | |
| Genetics only | Exposure to therapy | 2.08 (1.17 3.70) | .013 | 0.632 |
| TP53 mutated | 2.03 (0.84-4.95) | .118 | ||
| SF3B1 mutated | 5.31 (1.60-17.77) | .006 | ||
| OS | ||||
| Clinical | Exposure to therapy | 2.13 (1.10-4.14) | .026 | 0.792 |
| Lower Hb | 1.21 (1.01-1.47) | .042 | ||
| Lower PLT | 1.01 (1.01-1.01) | .015 | ||
| Higher RDW | 1.19 (1.07-1.32) | .001 | ||
| Modified CHRS | Exposure to therapy | 2.28 (1.20-4.31) | .012 | 0.662 |
| Abnormal cyto. | 2.20 (1.17-4.13) | .014 | ||
| Higher CHRS Score | 1.29 (1.10-1.53) | .002 | ||
| Genetics only | Exposure to therapy | 2.02 (1.05-3.85) | .034 | 0.607 |
| TP53 mutated | 2.03 (0.59-6.99) | .264 | ||
| Abnormal cyto. | 2.07 (1.09-3.93) | .006 | ||
| Model . | Variable . | HR (95% CI) . | P value . | C index . |
|---|---|---|---|---|
| PFS | ||||
| Clinical | Exposure to therapy | 1.98 (1.10-3.56) | .023 | |
| Lower Hb | 1.11 (0.93-1.33) | .250 | ||
| Lower PLT | 1.01 (1.01-1.01) | .014 | ||
| Higher RDW | 1.19 (1.07-1.31) | <.001 | 0.751 | |
| Higher MCV | 1.01 (0.98-1.05) | .463 | ||
| Modified CHRS | Exposure to therapy | 2.34 (1.35-4.05) | .002 | |
| Higher CHRS Score | 1.38 (1.19-1.60) | <.001 | 0.688 | |
| Genetics only | Exposure to therapy | 2.08 (1.17 3.70) | .013 | 0.632 |
| TP53 mutated | 2.03 (0.84-4.95) | .118 | ||
| SF3B1 mutated | 5.31 (1.60-17.77) | .006 | ||
| OS | ||||
| Clinical | Exposure to therapy | 2.13 (1.10-4.14) | .026 | 0.792 |
| Lower Hb | 1.21 (1.01-1.47) | .042 | ||
| Lower PLT | 1.01 (1.01-1.01) | .015 | ||
| Higher RDW | 1.19 (1.07-1.32) | .001 | ||
| Modified CHRS | Exposure to therapy | 2.28 (1.20-4.31) | .012 | 0.662 |
| Abnormal cyto. | 2.20 (1.17-4.13) | .014 | ||
| Higher CHRS Score | 1.29 (1.10-1.53) | .002 | ||
| Genetics only | Exposure to therapy | 2.02 (1.05-3.85) | .034 | 0.607 |
| TP53 mutated | 2.03 (0.59-6.99) | .264 | ||
| Abnormal cyto. | 2.07 (1.09-3.93) | .006 | ||
Variables in bold indicate P < 0.05. CHRS, clonal hematopoiesis risk score; cyto., cytogenetics; MCV, mean corpuscular volume.